抄録
The anti-tumor effects of selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) on several types of cancer cells have been reported. However, comparison of the anti-tumor effects of these drugs on human hepatocellular carcinoma (HepG2) cells has not been studied. We compared the anti-tumor effects of four SSRIs and two SNRIs on HepG2 cells. SSRIs and duloxetine dose-dependently decreased cell viability. Milnacipran had no effect on cell viability. The half-maximal inhibitory concentration was lower in the order of: sertraline, paroxetine, duloxetine, fluvoxamine, escitalopram, and milnacipran. Exposure to sertraline (2 μM) significantly increased caspase-3/7 activity. These results suggest that, of the agents tested here, sertraline had the highest sensitivity to HepG2 cells, and activation of the caspase pathway is involved in the anti-tumor effects of sertraline in HepG2 cells.
| 元の言語 | 英語 |
|---|---|
| ページ（範囲） | 1410-1414 |
| ページ数 | 5 |
| ジャーナル | Biological and Pharmaceutical Bulletin |
| 巻 | 38 |
| 発行部数 | 9 |
| DOI | |
| 出版物ステータス | 出版済み - 9 1 2015 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology
- Pharmaceutical Science
これを引用
Comparison of the anti-tumor effects of selective serotonin reuptake inhibitors as well as serotonin and norepinephrine reuptake inhibitors in human hepatocellular carcinoma cells. / Kuwahara, Jun; Yamada, Takaaki; Egashira, Nobuaki; Ueda, Mitsuyo; Zukeyama, Nina; Ushio, Soichiro; Masuda, Satohiro.
：: Biological and Pharmaceutical Bulletin, 巻 38, 番号 9, 01.09.2015, p. 1410-1414.研究成果: ジャーナルへの寄稿 › 記事
}
TY - JOUR
T1 - Comparison of the anti-tumor effects of selective serotonin reuptake inhibitors as well as serotonin and norepinephrine reuptake inhibitors in human hepatocellular carcinoma cells
AU - Kuwahara, Jun
AU - Yamada, Takaaki
AU - Egashira, Nobuaki
AU - Ueda, Mitsuyo
AU - Zukeyama, Nina
AU - Ushio, Soichiro
AU - Masuda, Satohiro
PY - 2015/9/1
Y1 - 2015/9/1
N2 - The anti-tumor effects of selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) on several types of cancer cells have been reported. However, comparison of the anti-tumor effects of these drugs on human hepatocellular carcinoma (HepG2) cells has not been studied. We compared the anti-tumor effects of four SSRIs and two SNRIs on HepG2 cells. SSRIs and duloxetine dose-dependently decreased cell viability. Milnacipran had no effect on cell viability. The half-maximal inhibitory concentration was lower in the order of: sertraline, paroxetine, duloxetine, fluvoxamine, escitalopram, and milnacipran. Exposure to sertraline (2 μM) significantly increased caspase-3/7 activity. These results suggest that, of the agents tested here, sertraline had the highest sensitivity to HepG2 cells, and activation of the caspase pathway is involved in the anti-tumor effects of sertraline in HepG2 cells.
AB - The anti-tumor effects of selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) on several types of cancer cells have been reported. However, comparison of the anti-tumor effects of these drugs on human hepatocellular carcinoma (HepG2) cells has not been studied. We compared the anti-tumor effects of four SSRIs and two SNRIs on HepG2 cells. SSRIs and duloxetine dose-dependently decreased cell viability. Milnacipran had no effect on cell viability. The half-maximal inhibitory concentration was lower in the order of: sertraline, paroxetine, duloxetine, fluvoxamine, escitalopram, and milnacipran. Exposure to sertraline (2 μM) significantly increased caspase-3/7 activity. These results suggest that, of the agents tested here, sertraline had the highest sensitivity to HepG2 cells, and activation of the caspase pathway is involved in the anti-tumor effects of sertraline in HepG2 cells.
UR - http://www.scopus.com/inward/record.url?scp=84941142845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941142845&partnerID=8YFLogxK
U2 - 10.1248/bpb.b15-00128
DO - 10.1248/bpb.b15-00128
M3 - Article
C2 - 26328498
AN - SCOPUS:84941142845
VL - 38
SP - 1410
EP - 1414
JO - Biological and Pharmaceutical Bulletin
JF - Biological and Pharmaceutical Bulletin
SN - 0918-6158
IS - 9
ER -